IP Library Granted Patent US 8,394,815
Granted Patent B2
US 8,394,815 · App. 12/976,122 · Granted Mar 12, 2013

2,4,5-trisubstituted imidazoles and their use as anti-microbial agents

Inventors: Raed H. Al-Qawasmeh (North York, CA); Aiping H. Young (Toronto, CA); Mario Huesca (Toronto, CA); Yoon S. Lee (Mississauga, CA)
Assignee: Lorus Therapeutics Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,394,815
App. No.
12/976,122
Granted
Mar 12, 2013
Kind
B2
Abstract

The present invention provides therapeutically effective 2,4,5-trisubstituted imidazole compounds, methods of preparing the same, and compositions comprising the compounds alone or in combination with other agents. The present invention further provides for the use of the compounds as anti-microbial agents. The anti-microbial properties of the compounds include anti-bacterial and/or anti-fungal activity.

Claims (73)

1. A compound of the structural formula:

or a salt thereof, wherein:

R4, R5, R6, R7, R8 and R9 are independently selected from hydrogen, halogen, hydroxyl, thiol, lower alkyl, substituted lower alkyl, lower alkenyl, substituted lower alkenyl, lower alkynyl, substituted lower alkynyl, alkylalkenyl, alkyl alkynyl, alkoxy, alkylthio, acyl, aryloxy, amino, amido, carboxyl, aryl, substituted aryl, heterocycle, heteroaryl, substituted heterocycle, heteroalkyl, cycloalkyl, substituted cycloalkyl, alkylcycloalkyl, alkylcycloheteroalkyl, nitro, or cyano;

R10 is H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, or acyl;

x is CR11;

y is CR12 or N;

z is CR13 or N;

r is CR14 or N;

x′ is CR15;

y′ is CR16 or N;

z′ is CR17 or N;

r′ is CR18 or N; and

R11, R12, R13, R14, R15, R16, R17 and R18 are independently selected from hydrogen, halogen, hydroxyl, thiol, lower alkyl, substituted lower alkyl, lower alkenyl, lower alkynyl, alkylalkenyl, alkyl alkynyl, alkoxy, alkylthio, acyl, aryloxy, amino, amido, carboxyl, aryl, substituted aryl, heterocycle, heteroaryl,

substituted heterocycle, heteroalkyl, cycloalkyl, substituted cycloalkyl, alkylcycloalkyl, alkylcycloheteroalkyl, nitro, or cyano;

wherein at least one of y, z, r, y′, z′ or r′ is N.

2. The compound according to claim 1 , wherein:

x is CR11;

y is CR12;

z is CR13;

r is N;

x′ is CR15;

y′ is CR16;

z′ is CR17; and

r′ is N.

3. The compound according to claim 1 , wherein:

R11, R12, R13, R15, R16 and R17 are independently hydrogen or halogen.

4. The compound according to claim 1 , wherein:

R11, R12, R13, R15, R16 and R17 are each hydrogen.

5. The compound according to claim 1 , wherein:

R5, R6, R7, R8, and R9 are independently hydrogen, halogen, lower alkyl, amino, carboxyl, or nitro.

6. The compound according to claim 1 , wherein:

R5, R6, R7, R8, and R9 are independently hydrogen, halogen, lower alkyl or carboxyl.

7. The compound according to claim 1 , wherein:

R5, R6, R7, R8, and R9 are independently hydrogen, halogen or lower alkyl.

8. The compound according to claim 1 , wherein:

R6 is hydrogen or halogen;

R9 is hydrogen or lower alkyl; and

R5, R7, R8 and R10 are each hydrogen.

9. The compound according to claim 1 , wherein:

R4 is hydrogen or acyl.

10. The compound according to claim 1 , wherein:

R4 is hydrogen.

11. The compound according to claim 1 , wherein:

x is CR11;

y is CR12;

z is CR13;

r is N;

x′ is CR15;

y′ is CR16;

z′ is CR17;

r′ is N;

R11, R12, R13, R15, R16, and R17 are each hydrogen;

R5, R6, R7, R8, and R9 are independently hydrogen, halogen or lower alkyl, and

R4 is hydrogen or acyl.

12. The compound according to claim 11 , wherein:

R4 is hydrogen.

13. The compound according to claim 1 , wherein:

x is CR11;

y is CR12;

z is CR13;

r is N;

x′ is CR15;

y′ is CR16;

z′ is CR17;

r′ is N;

R11, R12, R13, R15, R16, and R17 are each hydrogen;

R6 is hydrogen or halogen;

R9 is hydrogen or lower alkyl;

R5, R7, R8 and R10 are each hydrogen, and

R4 is hydrogen or acyl.

14. The compound according to claim 13 , wherein:

R4 is hydrogen.

15. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier or diluent.

Assignments (5)
CHANGE OF NAME Recorded Sep 22, 2014
From: LORUS THERAPEUTICS INC.
To: APTOSE BIOSCIENCES INC.
Reel/Frame 033793/0620 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2012
From: GENESENSE TECHNOLOGIES INC.
To: LORUS THERAPEUTICS INC.
Reel/Frame 027493/0292 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2012
From: 4325231 CANADA INC.
To: GENESENSE TECHNOLOGIES INC.
Reel/Frame 027493/0386 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2012
From: AL-QAWASMEH, RAED; YOUNG, ALPING H.; HUESCA, MARIO; LEE, YOON
To: LORUS THERAPEUTICS INC.
Reel/Frame 027493/0396 →
CHANGE OF NAME Recorded Jan 6, 2012
From: LORUS THERAPEUTICS INC.
To: 4325231 CANADA INC.
Reel/Frame 027493/0814 →
Priority Claims (1)
CA 2398765 · Aug 19, 2002 · national
Continuity (2)
Division 10525690
Related Publication 20110152337A1 · Jun 23, 2011